Johnson and Johnson Ordered to Pay $1.2 Billion for Mis-marketing Risperdal

by Anthony Chicotel, CANHR Staff Attorney

A judge recently ordered Johnson and Johnson to pay the state of Arkansas $1.2 billion for illegally marketing its antipsychotic drug Risperdal. The lawsuit included allegations that Johnson and Johnson illegally marketed Risperdal for uses not approved by the FDA, such as treating dementia. The order comes on the heels of other state judgments and settlements against Johnson and Johnson for several hundred million dollars. A similar lawsuit filed by the federal government remains on-going.

While the volume and size of the judgments against Johnson and Johnson seem meaningful and destined to dent big pharma sales, investors feel otherwise. The company’s stock price fell just seven cents (.1%) on the day the judgment was announced.


About achicotel

Anthony Chicotel is a staff attorney for CANHR. His areas of expertise include the rights of long-term care residents, nursing home litigation, health care decision-making, and conservatorships.
Print this page.

Responses to CANHR blog postings do not reflect the opinions of CANHR or its staff members.

One Response to Johnson and Johnson Ordered to Pay $1.2 Billion for Mis-marketing Risperdal

  1. DannyHaszard says:

    Risperdal reproached.
    Same saga here as Eli Lilly Zyprexa.
    Johnson and Johnson is a trusted brand we associate with babies.
    Risperdal,Zyprexa,as well as the other atypical antipsychotics, are being prescribed for children, even though this is an unapproved, off-label use. An estimated 2.5 million children are now taking atypical antipsychotics. Over half are being given them for Attention Deficit Hyperactivity Disorder,many of these foster children.
    Weight gain, increases in triglyceride levels and associated risks for (life-long) diabetes and cardiovascular disease.
    Eli Lilly made $65 BILLION on Zyprexa!

    Was called,”the most successful drug in the history of neuroscience”.

    *Tell the truth don’t be afraid*
    Daniel Haszard

Leave a Reply